Melanoma-associated antigen 10 peptide GLYDGMEHL presented by HLA-A*02:01 (MAGE-A10/HLA-A*02:01)

The MAGE-A10 peptide GLYDGMEHL presented by HLA-A*02:01 is a specific peptide-major histocompatibility complex (pMHC) target used in cancer immunotherapy. MAGE-A10 is a member of the cancer-testis antigen (CTA) family, which is typically expressed in various malignant tumors but restricted to the testis and placenta in healthy tissues, making it an ideal target for minimizing off-tumor toxicity (UniProt: P43363). The specific nonamer peptide GLYDGMEHL (residues 254-262) is processed and presented on the cell surface by the HLA-A*02:01 allele. Therapeutic strategies, such as T-cell receptor (TCR) engineered T-cell therapies like ADP-A2M10, are designed to recognize this specific complex and induce a cytotoxic immune response against cancer cells (ClinicalTrials.gov: NCT02858310). Clinical development has focused on patients with HLA-A*02:01-positive tumors that overexpress MAGE-A10, including melanoma and lung cancers. However, a significant challenge in targeting this complex is the potential for cross-reactivity with similar peptides found in healthy tissues, necessitating rigorous preclinical safety screening (PubMed: 28971930).

Other names

MAGE-A10(254-262)GLYDGMEHL-HLA-A*02:01 complexMelanoma-associated antigen 10

T-cell receptor (TCR) mediated recognition and lysis of tumor cells expressing the MAGE-A10 peptide-MHC complex.